Immunotec Reports Issuance of Options

VAUDREUIL-DORION, QUEBEC--(Marketwired - Sept. 22, 2015) - Immunotec Inc. (TSX VENTURE:IMM), a direct-to-consumer company and a leader in the nutritional industry (the "Company" or "Immunotec"), today announced that pursuant to the Immunotec Stock Option Plan, an officer was granted options entitling him to acquire up to 100,000 common shares of the Company (the "Shares"). The exercise price of such options was established at $0.265, which is the closing price of the Shares on the TSX Venture Exchange the day before their issuance. These options will vest over a three-year period, with one-third (1/3) which will vest on each of the first, second and third anniversaries of the date of the grant. Each option is exercisable, once vested, for a period of five years from the date of grant.

About Immunotec Inc.

Immunotec is a Canadian-based Company that develops, manufactures, markets and sells research-driven nutritional products through direct-to-consumer sales channels in Canada, the U.S. and Mexico. The Company offers an extensive family of nutritional products targeting health, wellness, weight management, as well as energy and performance. The Immunocal family of products is supported by over 40 published articles and supporting science in medical and scientific literature.

Please visit us at www.immunotec.com for additional information.

The Company files its continuous disclosure documents on the SEDAR database at www.sedar.com and on the Company's website at www.immunotec.com. The common shares of the Company are listed on the TSX Venture Exchange under the ticker symbol IMM. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.